Claims for Patent: 6,004,768

Summary for Patent: 6,004,768

Title:	Biosensors, extracorporeal devices and methods for detecting substances using crosslinked protein crystals
Abstract:	Proteins such as enzymes and antibodies are immobilized by crosslinking crystals of the proteins such as microcrystals having a cross-section of 10.sup.-1 mm or less with a multifunctional crosslinking agent. The crosslinked protein crystals may be lyophilized for storage. Crystals of an enzyme such as thermolysin, elastase, asparaginase, lysozyme, lipase or urease may be crosslinked to provide crosslinked enzyme crystals that retain at least 91% activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme to lose at least 94% of its initial activity under the same conditions. A preferred Pronase.TM.:enzyme ratio is 1:40. Crosslinked enzyme or antibody crystals may be used in an assay, diagnostic kit or biosensor for detecting an analyte, in an extracorporeal device for altering a component of a fluid, in producing a product such as using crosslinked thermolysin crystals to produce aspartame, in separating a substance from a mixture, and in therapy.
Inventor(s):	Navia; Manuel A. (Lexington, MA), St. Clair; Nancy L. (Charlestown, MA)
Assignee:	Vertex Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	08/484,238
Patent Claims:	1. A biosensor for detecting an analyte of interest in a fluid, comprising: (a) a protein crystal crosslinked with a multifunctional crosslinking agent, said crosslinked protein crystal having resistance to exogenous proteolysis, such that said crosslinked protein crystal retains at least 91% of its stability, as measured in terms of degradation, after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the protein that is crystallized to form said protein crystal that is crosslinked to lose at least 94% of its stability, as measured in terms of degradation, under the same conditions, wherein said protein has the activity of acting on the analyte of interest or on a reactant in a reaction in which the analyte of interest participates; (b) a retaining means for said crosslinked protein crystal, said retaining means consisting of a material which allows contact between said crosslinked protein crystal and a fluid, said fluid containing either (1) the analyte upon which said protein acts or (2) a reactant in a reaction in which the analyte participates; and (c) a signal transducer which produces a signal in the presence of the analyte. 2. A biosensor for detecting an analyte of interest in a fluid, comprising: (a) an enzyme crystal crosslinked with a multifunctional crosslinking agent, said crosslinked enzyme crystal having resistance to exogenous proteolysis, such that said crosslinked enzyme crystal retains at least 91% of its initial activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme that is crystallized to form said enzyme crystal that is crosslinked to lose at least 94% of its initial activity under the same conditions, wherein said enzyme has the activity of acting on the analyte of interest or on a reactant in a reaction in which the analyte of interest participates; (b) a retaining means for said crosslinked enzyme crystal, said retaining means consisting of a material which allows contact between said crosslinked enzyme crystal and a fluid, said fluid containing either (1) the analyte upon which said enzyme acts or (2) a reactant in a reaction in which the analyte participates; and (c) a signal transducer which produces a signal in the presence of the analyte. 3. The biosensor according to claim 1 or 2, wherein said crystal is a microcrystal. 4. The biosensor according to claim 3, wherein said microcrystal has a cross-section of 10.sup.-1 mm or less. 5. The biosensor according to claim 2, wherein said enzyme is a hydrolase. 6. The biosensor according to claim 5, wherein said hydrolase is selected from the group consisting of thermolysin, elastase, asparaginase, lysozyme and urease. 7. The biosensor according to claim 5, wherein said hydrolase is an esterase. 8. The biosensor according to claim 5, wherein said hydrolase is a lipase. 9. The biosensor according to claim 1 or 2, wherein said biosensor further comprises means for detecting the activity of said protein or enzyme on said analyte or reactant. 10. The biosensor according to claim 9, wherein said means for detecting the activity of said protein or enzyme on said analyte or reactant is selected from the group consisting of pH electrodes, light sensing devices, heat sensing devices and means for detecting electrical charge. 11. The biosensor according to claim 1 or 2, wherein said analyte is selected from the group consisting of glucose, creatinine, urea, lactate, glucose-6-phosphate, sucrose, ATP, ethanol, acetic acid, formic acid, cholesterol, uric acid, methotrexate, carbon dioxide, amino acids, phosphates, penicillin, nitrates, nitrites, sulphates and succinate. 12. An extracorporeal device for use in altering a component of a fluid, comprising: (a) a protein crystal crosslinked with a multifunctional crosslinking agent, said crosslinked protein crystal having resistance to exogenous proteolysis, such that said crosslinked protein crystal retains at least 91% of its stability, as measured in terms of degradation, after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the protein that is crystallized to form said protein crystal that is crosslinked to lose at least 94% of its stability, as measured in terms of degradation, under the same conditions, wherein said protein has the activity of acting on the component or on a reactant in a reaction in which the component participates; and (b) a retaining means for said crosslinked protein crystal, said retaining means consisting of a material which allows contact between said crosslinked protein crystal and a fluid, said fluid containing either (1) the component upon which said protein acts or (2) a reactant in a reaction in which the component participates. 13. An extracorporeal device for use in altering a component of a fluid, comprising: (a) an enzyme crystal crosslinked with a multifunctional crosslinking agent, said crosslinked enzyme crystal having resistance to exogenous proteolysis, such that said crosslinked enzyme crystal retains at least 91% of its initial activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme that is crystallized to form said enzyme crystal that is crosslinked to lose at least 94% of its initial activity under the same conditions, wherein said enzyme has the activity of acting on the component or on a reactant in a reaction in which the component participates; and (b) a retaining means for said crosslinked enzyme crystal, said retaining means consisting of a material which allows contact between said crosslinked enzyme crystal and a fluid, said fluid containing either (1) the component upon which said enzyme acts or (2) a reactant in a reaction in which the component participates. 14. The extracorporeal device according to claim 12 or 13, wherein said crystal is a microcrystal. 15. The extracorporeal device according to claim 14, wherein said microcrystal has a cross-section of 10.sup.-1 mm or less. 16. The extracorporeal device according to claim 13, wherein said enzyme is a hydrolase. 17. The extracorporeal device according to claim 16, wherein said hydrolase is selected from the group consisting of thermolysin, elastase, asparaginase, lysozyme and urease. 18. The extracorporeal device according to claim 16, wherein said hydrolase is an esterase. 19. The extracorporeal device according to claim 16, wherein said hydrolase is a lipase. 20. The extracorporeal device according to claim 12 or 13, wherein said device further comprises a deheparinization device located at an effluent of the extracorporeal device. 21. The extracorporeal device according to claim 20, wherein said deheparinization device is selected from the group consisting of continuous arteriovenous hemofiltration devices and extracorporeal membrane oxygenators. 22. The extracorporeal device according to claim 12 or 13, wherein said component is selected from the group consisting of heparin, bilirubin, methotrexate, amino acids, urea and ammonia. 23. The extracorporeal device according to claim 12 or 13, wherein said retaining means is a porous material on which said crosslinked protein or enzyme crystal is retained or a tube in which said crosslinked protein or enzyme crystal is present. 24. A method for detecting the presence of a substance in a sample comprising the steps of: (a) contacting the sample with a protein which is a protein crystal crosslinked with a multifunctional crosslinking agent, said crosslinked protein crystal having resistance to exogenous proteolysis, such that said crosslinked protein crystal retains at least 91% of its stability, as measured in terms of degradation, after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the protein that is crystallized to form said protein crystal that is crosslinked to lose at least 94% of its stability, as measured in terms of degradation, under the same conditions, wherein said protein has the activity of acting on the substance or on a reactant in a reaction in which the substance participates to cause a detectable change, under conditions and for a time sufficient to permit said activity; and (b) using a detection means to detect the detectable change. 25. A method for detecting the presence of a substance in a sample comprising the steps of: (a) contacting the sample with an enzyme which is an enzyme crystal crosslinked with a multifunctional crosslinking agent, said crosslinked enzyme crystal having resistance to exogenous proteolysis, such that said crosslinked enzyme crystal retains at least 91%, of its initial activity after incubation for three hours in the presence of a concentration of Pronase.TM. that causes the soluble uncrosslinked form of the enzyme that is crystallized to form said enzyme crystal that is crosslinked to lose at least 94% of its initial activity under the same conditions, wherein said enzyme has the activity of acting on the substance or on a reactant in a reaction in which the substance participates to cause a detectable change, under conditions and for a time sufficient to permit said activity; and (b) using a detection means to detect the detectable change. 26. The method according to claim 24 or 25, wherein said crystal is a microcrystal. 27. The method according to claim 26, wherein said microcrystal has a cross-section of 10.sup.-1 mm or less. 28. The method according to claim 25, wherein said enzyme is a hydrolase. 29. The method according to claim 28, wherein said hydrolase is selected from the group consisting of thermolysin, elastase, asparaginase, lysozyme and urease. 30. The method according to claim 28, wherein said hydrolase is an esterase. 31. The method according to claim 28, wherein said hydrolase is a lipase. 32. The method according to claim 24 or 25, wherein the detectable change is selected from the group consisting of change in pH, production of light, production of heat and change in electrical potential.

Details for Patent 6,004,768

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2016-12-21